Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Development
Arvinas partners with Novartis for prostate cancer drugs
by Sarah Braner
April 18, 2024
| A version of this story appeared in
Volume 102, Issue 12
Novartis has agreed to license Arvinas’s protein-degradation prostate cancer drug ARV-766. This clinical-stage candidate targets mutated androgen receptors that are thought to confer resistance to cancer drugs. Arvinas has also sold to Novartis its preclinical program that targets AR-V7, a variant androgen receptor that may also allow cancer cells to evade existing treatments. Arvinas will receive an up-front payment of $150 million, with the potential for $1 billion in milestone and royalty payments.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter